Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALECNASDAQ:BCYCNASDAQ:KURANASDAQ:MNMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.54-4.9%$1.20$0.87▼$6.78$153.99M0.71846,284 shs408,838 shsBCYCBicycle Therapeutics$8.37-3.7%$8.07$6.10▼$28.67$579.66M1.46388,725 shs125,676 shsKURAKura Oncology$6.44-3.3%$6.13$5.41▼$23.48$557.54M0.41.23 million shs1.12 million shsMNMDMind Medicine (MindMed)$7.17-1.8%$6.56$4.70▼$10.44$541.72M2.521.36 million shs985,016 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-0.61%+14.89%+45.95%+11.72%-65.53%BCYCBicycle Therapeutics-0.80%+2.24%+7.15%-10.32%-64.49%KURAKura Oncology-3.76%+1.37%+14.83%-6.72%-69.28%MNMDMind Medicine (MindMed)-1.35%-5.07%+14.60%+14.96%-7.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.3738 of 5 stars3.11.00.04.52.21.70.0BCYCBicycle Therapeutics3.3545 of 5 stars4.41.00.00.02.04.20.6KURAKura Oncology4.3493 of 5 stars4.51.00.04.73.20.80.6MNMDMind Medicine (MindMed)1.9298 of 5 stars3.60.00.00.03.40.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00159.74% UpsideBCYCBicycle Therapeutics 2.70Moderate Buy$25.00198.69% UpsideKURAKura Oncology 2.93Moderate Buy$24.50280.43% UpsideMNMDMind Medicine (MindMed) 3.27Buy$25.50255.65% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, BCYC, MNMD, and KURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.005/19/2025KURAKura OncologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.005/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.005/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/5/2025BCYCBicycle TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.005/2/2025BCYCBicycle TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.005/2/2025BCYCBicycle TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.005/2/2025BCYCBicycle TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$26.00 ➝ $22.005/2/2025BCYCBicycle TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/2/2025KURAKura OncologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$88.34M1.74N/AN/A$1.41 per share1.09BCYCBicycle Therapeutics$25.72M22.54N/AN/A$12.35 per share0.68KURAKura Oncology$67.99M8.20N/AN/A$5.35 per share1.20MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$130.39M-$1.26N/AN/AN/A-257.54%-108.77%-27.03%8/6/2025 (Estimated)BCYCBicycle Therapeutics-$180.66M-$3.14N/AN/AN/A-450.64%-27.35%-20.81%8/5/2025 (Estimated)KURAKura Oncology-$152.63M-$2.10N/AN/AN/AN/A-44.09%-39.57%8/6/2025 (Estimated)MNMDMind Medicine (MindMed)-$95.73M-$1.29N/AN/AN/AN/A-47.56%-35.55%8/12/2025 (Estimated)Latest ALEC, BCYC, MNMD, and KURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A5/1/2025Q1 2025BCYCBicycle Therapeutics-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 million5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ABCYCBicycle TherapeuticsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlectorN/A3.293.29BCYCBicycle TherapeuticsN/A17.1317.13KURAKura Oncology0.0211.4711.47MNMDMind Medicine (MindMed)0.099.009.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%BCYCBicycle Therapeutics86.15%KURAKura OncologyN/AMNMDMind Medicine (MindMed)27.91%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%BCYCBicycle Therapeutics22.90%KURAKura Oncology6.40%MNMDMind Medicine (MindMed)2.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million89.02 millionOptionableBCYCBicycle Therapeutics24069.25 million63.18 millionOptionableKURAKura Oncology13086.58 million73.49 millionOptionableMNMDMind Medicine (MindMed)4075.55 million71.68 millionOptionableALEC, BCYC, MNMD, and KURA HeadlinesRecent News About These CompaniesCantor Fitzgerald Comments on MNMD FY2026 EarningsJune 12 at 2:49 AM | americanbankingnews.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives $25.50 Average Price Target from AnalystsJune 12 at 1:29 AM | americanbankingnews.comMind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 4.8% - Here's WhyJune 11 at 3:18 PM | marketbeat.comEquities Analysts Offer Predictions for MNMD FY2026 EarningsJune 10 at 8:56 AM | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Recommendation of "Buy" by BrokeragesJune 9, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Sold by Two Sigma Investments LPJune 5, 2025 | marketbeat.comMillennium Management LLC Increases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)June 5, 2025 | marketbeat.comWhy Mind Medicine Gave Investors a Powerful Buzz in MayJune 4, 2025 | msn.comBank of America Corp DE Reduces Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)June 4, 2025 | marketbeat.comWall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to TradeJune 2, 2025 | zacks.comMindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial OfficerMay 27, 2025 | finance.yahoo.comHC Wainwright Has Pessimistic Outlook of MNMD Q3 EarningsMay 27, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for MNMD Q1 Earnings?May 25, 2025 | marketbeat.comCantor Fitzgerald Has Negative View of MNMD FY2025 EarningsMay 25, 2025 | marketbeat.comNorthern Trust Corp Has $4.77 Million Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 24, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Acquired by AWM Investment Company Inc.May 23, 2025 | marketbeat.comTang Capital Management LLC Acquires New Shares in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 20, 2025 | marketbeat.comMindMed Announces New Employee Inducement GrantsMay 19, 2025 | businesswire.comCantor Fitzgerald Upgrades Mind Medicine (MindMed) (NASDAQ:MNMD) to "Strong-Buy"May 17, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Rating of "Buy" by AnalystsMay 17, 2025 | marketbeat.comCantor Fitzgerald Forecasts MNMD FY2025 EarningsMay 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALEC, BCYC, MNMD, and KURA Company DescriptionsAlector NASDAQ:ALEC$1.54 -0.08 (-4.94%) Closing price 04:00 PM EasternExtended Trading$1.54 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Bicycle Therapeutics NASDAQ:BCYC$8.37 -0.32 (-3.68%) Closing price 04:00 PM EasternExtended Trading$8.10 -0.27 (-3.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Kura Oncology NASDAQ:KURA$6.44 -0.22 (-3.30%) Closing price 04:00 PM EasternExtended Trading$6.49 +0.05 (+0.76%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Mind Medicine (MindMed) NASDAQ:MNMD$7.17 -0.13 (-1.78%) Closing price 04:00 PM EasternExtended Trading$7.15 -0.02 (-0.28%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
